Skip to content

Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour

Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03448822
Acronym
SENATOR
Enrollment
76
Registered
2018-02-28
Start date
2018-09-01
Completion date
2026-04-01
Last updated
2018-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Testicular Germ Cell Tumor

Brief summary

Assessment of accuracy of sentinel node biopsy, defined as the false negative rate.

Detailed description

Current practice in patients with Clinical Stage I (CS I) testicular germ cell tumour is active surveillance after orchiectomy, with relapses occurring in 15-20% of patients. The majority of relapses occur in the lymph nodes as lymphogenic spread is the dominant route of dissemination. A sentinel node procedure, in which the sentinel lymph node is resected and pathologically examined, could be more reliable to identify patients who are likely to relapse. Early identification of patients with micro-metastases in the sentinel node makes it possible to treat these patients at the earliest possible moment. Absence of metastases could lead in the future to a less intensive follow up protocol than the present one.

Interventions

a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis

Sponsors

The Netherlands Cancer Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients suspected of testicular germ cell tumour, based on physical examination, ultrasound imaging, and tumour markers * Patients 18 years and older * No evidence of metastases on first staging (thoraco-abdominopelvic CT) * Written and signed informed consent

Exclusion criteria

* Patients with evidence of metastases at first staging * Patients with a second primary tumour * Patients with recent (\< 6 months before diagnosis) surgical treatment to the external genitals or recent surgical intervention in the inguinal or retroperitoneal regions * Patients with previous abdominal surgery, necessitating open surgical approach for the sentinel node biopsy

Design outcomes

Primary

MeasureTime frameDescription
identify patients witha low risk of cancer recurrenceincluded in current active surveillance protocols.surgery 1 day, follow up 5 yearsidentify patients who have such a low risk of cancer recurrence that it is not necessary anymore to be included in current active surveillance protocols by removing the sentinal lymph node to check for occult metastasis

Contacts

Primary ContactJoost Blok, MD
j.blok@nki.nl0031 20 5129111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026